|171.43||+0.2887||+0.17%||Vol 1.69M||1Y Perf -62.53%|
|Aug 10th, 2022 00:41 DELAYED|
|2.74 1.60%||- -|
|Target Price||229.42||Analyst Rating||Hold 2.67|
|Potential %||34.42||Finscreener Ranking||★★★★+ 55.33|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 61.50|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 73.22|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||14.62||Earnings Rating||Sell|
|Market Cap||67.06B||Earnings Date||3rd Aug 2022|
Today's Price Range
|3 Years||1 183.87%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||4.50|
|EPS Growth Next 5 Years %||6.50|
|Avg. Weekly Volume||7.00M|
|Avg. Monthly Volume||4.56M|
|Avg. Quarterly Volume||5.27M|
Moderna Inc. (NASDAQ: MRNA) stock closed at 171.14 per share at the end of the most recent trading day (a -6.45% change compared to the prior day closing price) with a volume of 5.06M shares and market capitalization of 67.06B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1300 people. Moderna Inc. CEO is Stephane Bancel.
The one-year performance of Moderna Inc. stock is -62.53%, while year-to-date (YTD) performance is -32.62%. MRNA stock has a five-year performance of %. Its 52-week range is between 115.61 and 497.49, which gives MRNA stock a 52-week price range ratio of 14.62%
Moderna Inc. currently has a PE ratio of 4.90, a price-to-book (PB) ratio of 3.89, a price-to-sale (PS) ratio of 3.56, a price to cashflow ratio of 5.40, a PEG ratio of 2.32, a ROA of 73.94%, a ROC of 131.22% and a ROE of 141.44%. The company’s profit margin is 64.93%, its EBITDA margin is 73.30%, and its revenue ttm is $18.25 Billion , which makes it $45.87 revenue per share.
Of the last four earnings reports from Moderna Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $4.50 for the next earnings report. Moderna Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Moderna Inc. is Hold (2.67), with a target price of $229.42, which is +34.42% compared to the current price. The earnings rating for Moderna Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Moderna Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Moderna Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.66, ATR14 : 10.85, CCI20 : 41.49, Chaikin Money Flow : 0.06, MACD : 6.96, Money Flow Index : 43.13, ROC : 4.66, RSI : 44.74, STOCH (14,3) : 42.46, STOCH RSI : 0.41, UO : 53.38, Williams %R : -57.54), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Moderna Inc. in the last 12-months were: David W. Meline (Option Excercise at a value of $0), David W. Meline (Sold 619 shares of value $98 354 ), Elizabeth E. Tallett (Option Excercise at a value of $0), Elizabeth G. Nabel (Option Excercise at a value of $0), Juan Andres (Option Excercise at a value of $5 620 972), Juan Andres (Sold 440 309 shares of value $138 696 510 ), Noubar B. Afeyan (Option Excercise at a value of $0), Paul Sagan (Option Excercise at a value of $0), Paul Sagan (Sold 2 250 shares of value $708 525 ), Robert S. Langer (Option Excercise at a value of $0), Sandra J. Horning (Option Excercise at a value of $0), Shannon Thyme Klinger (Option Excercise at a value of $637 560), Shannon Thyme Klinger (Sold 1 265 shares of value $187 371 ), Stephane Bancel (Option Excercise at a value of $712 800), Stephane Bancel (Sold 1 553 500 shares of value $307 718 459 ), Stephen Berenson (Option Excercise at a value of $0), Stephen Hoge (Option Excercise at a value of $5 611 436), Stephen Hoge (Sold 593 305 shares of value $143 571 316 )
Wed, 03 Aug 2022 19:15 GMT Moderna (MRNA) Receives a Buy from Brookline Capital Markets- TipRanks. All rights reserved.
Fri, 22 Jul 2022 09:42 GMT Moderna (MRNA) Gets a Hold Rating from Jefferies- TipRanks. All rights reserved.
Fri, 24 Jun 2022 11:25 GMT Moderna Gains 5% on Vaccine Recommendation by CDC- TipRanks. All rights reserved.
Wed, 15 Jun 2022 11:21 GMT FDAs COVID Vaccine for Children Between Ages 6 & 17- TipRanks. All rights reserved.
Mon, 13 Jun 2022 22:40 GMT Moderna (MRNA) Gets a Buy Rating from Goldman Sachs- TipRanks. All rights reserved.
Wed, 08 Jun 2022 07:30 GMT Novavax Wins Positive Recommendation for COVID-19 Vaccine in the U.S.- TipRanks. All rights reserved.
Tue, 07 Jun 2022 14:05 GMT Moderna (MRNA) Gets a Buy Rating from Brookline Capital Markets- TipRanks. All rights reserved.
Thu, 05 May 2022 13:26 GMT Moderna Stock Gets a Booster Dose of Upbeat Q1 Results- TipRanks. All rights reserved.
Wed, 04 May 2022 16:55 GMT Moderna Wins on Vaccine Sales- TipRanks. All rights reserved.
Tue, 03 May 2022 23:32 GMT This Analyst Says to Be Positive About Novavaxs Covid Vaccine Chances- TipRanks. All rights reserved.
Mon, 11 Apr 2022 15:32 GMT Moderna Recalls 764,900 COVID-19 Doses in Europe- TipRanks. All rights reserved.
Wed, 06 Apr 2022 16:48 GMT Moderna: Key Takeaways From Recent Vaccine Day- TipRanks. All rights reserved.
Fri, 25 Mar 2022 11:05 GMT Moderna (MRNA) Receives a Hold from Needham- TipRanks. All rights reserved.
Thu, 03 Mar 2022 12:16 GMT Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Beam Therapeutics (BEAM)- TipRanks. All rights reserved.
Wed, 02 Mar 2022 14:12 GMT MRNA Stock: Could Vaccine Stocks Suffer Setback- TipRanks. All rights reserved.
Mon, 28 Feb 2022 22:46 GMT Moderna: Pipeline Development Is the Key in 2022, Says Morgan Stanley- TipRanks. All rights reserved.
Fri, 25 Feb 2022 07:55 GMT Moderna Soars 15% on Stellar Q4 Results- TipRanks. All rights reserved.
Wed, 23 Feb 2022 17:30 GMT Moderna Stock: More than a One-Hit-Wonder- TipRanks. All rights reserved.
Thu, 10 Feb 2022 17:06 GMT Moderna Stock: Falling Knife May Be Worth Catching- TipRanks. All rights reserved.
Wed, 09 Feb 2022 08:00 GMT Novavax Dives After Vaccine Delivery Numbers Falter- TipRanks. All rights reserved.
Fri, 28 Jan 2022 12:26 GMT Moderna (MRNA) Gets a Sell Rating from Leerink Partners- TipRanks. All rights reserved.
Thu, 27 Jan 2022 20:05 GMT Moderna: Valuation Seems More Reasonable at Current Levels, Says Analyst- TipRanks. All rights reserved.
Mon, 24 Jan 2022 14:17 GMT As Omicron Rages, Will Moderna Stock Benefit- TipRanks. All rights reserved.
Mon, 17 Jan 2022 15:57 GMT Moderna May Need a Booster of its Own- TipRanks. All rights reserved.
Fri, 14 Jan 2022 16:19 GMT In Search of a Better Covid Vaccine, This Analyst Taps Ocugen- TipRanks. All rights reserved.
Mon, 10 Jan 2022 14:46 GMT Moderna Booster Wait Time Reduced to 5 Months- TipRanks. All rights reserved.
Wed, 05 Jan 2022 17:54 GMT Moderna Is Undervalued and Has Billions to Reinvest- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.